IL299301A - Compositions and methods for the treatment of obsessive compulsive disorder - Google Patents

Compositions and methods for the treatment of obsessive compulsive disorder

Info

Publication number
IL299301A
IL299301A IL299301A IL29930122A IL299301A IL 299301 A IL299301 A IL 299301A IL 299301 A IL299301 A IL 299301A IL 29930122 A IL29930122 A IL 29930122A IL 299301 A IL299301 A IL 299301A
Authority
IL
Israel
Prior art keywords
compositions
methods
compulsive disorder
treating obsessive
obsessive
Prior art date
Application number
IL299301A
Other languages
English (en)
Hebrew (he)
Inventor
Vladimir Coric
Robert Berman
Loren Aguiar
Original Assignee
Biohaven Therapeutics Ltd
Vladimir Coric
Robert Berman
Loren Aguiar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd, Vladimir Coric, Robert Berman, Loren Aguiar filed Critical Biohaven Therapeutics Ltd
Publication of IL299301A publication Critical patent/IL299301A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL299301A 2020-06-24 2021-06-24 Compositions and methods for the treatment of obsessive compulsive disorder IL299301A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063043681P 2020-06-24 2020-06-24
PCT/US2021/038789 WO2021262914A1 (en) 2020-06-24 2021-06-24 Compositions and methods for treating obsessive-compulsive disorder

Publications (1)

Publication Number Publication Date
IL299301A true IL299301A (en) 2023-02-01

Family

ID=79281806

Family Applications (1)

Application Number Title Priority Date Filing Date
IL299301A IL299301A (en) 2020-06-24 2021-06-24 Compositions and methods for the treatment of obsessive compulsive disorder

Country Status (12)

Country Link
US (1) US20230181541A1 (cg-RX-API-DMAC7.html)
EP (1) EP4171554A4 (cg-RX-API-DMAC7.html)
JP (1) JP7805969B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230027189A (cg-RX-API-DMAC7.html)
CN (1) CN115968312A (cg-RX-API-DMAC7.html)
AU (1) AU2021297249A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022025901A2 (cg-RX-API-DMAC7.html)
CA (1) CA3187323A1 (cg-RX-API-DMAC7.html)
IL (1) IL299301A (cg-RX-API-DMAC7.html)
MX (1) MX2022016174A (cg-RX-API-DMAC7.html)
PH (1) PH12022553441A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021262914A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP2400349A1 (hu) * 2024-07-05 2026-01-28 Egis Gyógyszergyár Zrt. Troriluzole-hidroklorid-sók

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2819303T3 (es) 2005-04-05 2021-04-15 Univ Yale Agentes moduladores del glutamato en el tratamiento de trastornos mentales
DK3265448T3 (da) 2015-03-03 2022-03-28 Biohaven Therapeutics Ltd Riluzol-prodrugs og anvendelse deraf
DK3297619T3 (da) 2015-05-22 2022-08-15 Vistagen Therapeutics Inc Terapeutiske anvendelser af L-4-chlorkynurenin
US10751345B2 (en) 2018-02-21 2020-08-25 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
CN112203692A (zh) 2018-05-27 2021-01-08 拜尔哈文制药股份有限公司 利鲁唑口腔崩解片用于治疗疾病的用途
JP2021530543A (ja) 2018-07-22 2021-11-11 バイオヘイブン・セラピューティクス・リミテッドBiohaven Therapeutics Ltd. アルツハイマー病を処置するためのリルゾールプロドラッグの使用
CN112584831A (zh) 2018-08-16 2021-03-30 拜奥海芬治疗学有限公司 利鲁唑口腔崩解片用于治疗疾病的用途

Also Published As

Publication number Publication date
CN115968312A (zh) 2023-04-14
KR20230027189A (ko) 2023-02-27
PH12022553441A1 (en) 2024-03-04
EP4171554A1 (en) 2023-05-03
JP2023531919A (ja) 2023-07-26
JP7805969B2 (ja) 2026-01-26
AU2021297249A1 (en) 2023-02-23
CA3187323A1 (en) 2021-12-30
MX2022016174A (es) 2023-01-24
BR112022025901A2 (pt) 2023-01-10
WO2021262914A1 (en) 2021-12-30
US20230181541A1 (en) 2023-06-15
EP4171554A4 (en) 2024-07-31

Similar Documents

Publication Publication Date Title
IL309296A (en) Methods and compositions for the treatment of angiotensinogen-related disorder (AGT-)
ZA202207394B (en) Compositions and methods for treating hemoglobinopathies
IL286350A (en) Preparations and methods for the treatment of cancer
IL288914A (en) Preparations and methods for the treatment of cancer
SG11202011080QA (en) Methods and compositions for treating cancer
GB2578539B (en) Compositions and methods for preventing or treating muscle conditions
ZA202104870B (en) Methods and compositions for treating cancer
IL285886A (en) Preparations and methods for the treatment of laminopathy
IL285796A (en) Methods and preparations for the treatment of cancer
SG11202012435UA (en) Compositions and methods for treating cancer
EP3976187A4 (en) Methods and compositions for treating epilepsy
IL287982A (en) Preparations and methods for the treatment of cancer
SG11202012055PA (en) Methods and compositions for preventing or treating calciphylaxis
IL299295A (en) Methods and compositions for treating hemophilia
IL305806A (en) Compounds and methods for the treatment of polycythemia
IL286153A (en) Methods and preparations for the treatment of cancer
IL282948B2 (en) Cancer treatment preparations and methods
IL309120A (en) Methods and compositions for the treatment of cancer
IL309071A (en) Methods and compositions for the treatment of cancer
EP4251161A4 (en) TREATMENT OF OCD WITH BOL-148
GB202010449D0 (en) Method and composition
IL312846A (en) Methods and preparations for the treatment of cancer
IL289795A (en) Compositions and methods for treating cerebral vasospasm
HK40085044A (en) Compositions and methods for treating obsessive-compulsive disorder
IL285036A (en) Methods and preparations for the treatment of cancer